Irfan Ahmed, MD
Nephrology · Chandler, AZNPI 1750540498
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,741 of the $5,493 with a category attached, or 86.3%. It is spread thinly across 29 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,981, 5.1 times the $391 reported in 2019.
Across 257 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$783
- Amgen$749
- OPKO Pharmaceuticals, LLC$712
- Otsuka America Pharmaceutical, Inc.$547
- Mallinckrodt Hospital Products Inc.$493
- Travere Therapeutics, Inc.$333
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,74186%
- Education$75214%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 40 | $783 |
| Amgen(2 entities) | 43 | $749 |
| OPKO Pharmaceuticals, LLC | 38 | $712 |
| Otsuka America Pharmaceutical, Inc. | 25 | $547 |
| Mallinckrodt Hospital Products Inc. | 16 | $493 |
| Travere Therapeutics, Inc. | 13 | $333 |
| Bayer | 16 | $321 |
| Vifor Pharma, Inc. | 7 | $159 |
| Daiichi Sankyo Inc. | 7 | $151 |
| Akebia Therapeutics Inc | 7 | $143 |
| Boehringer Ingelheim | 5 | $107 |
| Novartis | 5 | $99 |
| Calliditas Therapeutics US Inc. | 3 | $93 |
| Intuitive Surgical | 1 | $89 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $87 |
| Ardelyx, Inc. | 5 | $83 |
| Shield Therapeutics Inc | 3 | $80 |
| GSK | 4 | $76 |
| Baxter Healthcare | 2 | $70 |
| Novo Nordisk | 2 | $57 |
| Renalytix AI, Inc. | 2 | $52 |
| ANI Pharmaceuticals, Inc. | 2 | $40 |
| Lilly USA, LLC | 2 | $33 |
| Sanofi | 1 | $31 |
| Aurinia Pharma U.S., Inc. | 1 | $29 |
| Chiesi USA, Inc. | 1 | $22 |
| Boston Scientific | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Nxstage Medical, Inc. | 1 | $16 |
How this compares
$5,493 in reported general payments places this provider in the 80th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 173 | $133,197 |
| JardianceEmpagliflozin | 86 | $67,910 |
| KerendiaFinerenone | 47 | $42,636 |
| RayaldeeCalcifediol | 30 | $41,688 |
| LokelmaSodium Zirconium Cyclosilicate | 57 | $35,821 |
| VeltassaPatiromer Calcium Sorbitex | 47 | $33,019 |
| VelphoroSucroferric Oxyhydroxide | 19 | $29,999 |
| DapagliflozinDapagliflozin Propanediol | 15 | $7,494 |
| Fluconazole | 55 | $3,150 |
| Bumetanide | 62 | $1,849 |
| Nifedipine ErNifedipine | 99 | $1,495 |
| Sevelamer Carbonate | 29 | $1,316 |
| Labetalol Hcl | 51 | $1,170 |
| Valsartan | 50 | $1,008 |
| Calcitriol | 54 | $944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $783 | $169,018230 claims |
| Boehringer IngelheimJardiance | $107 | $67,91086 claims |
| BayerKerendia | $321 | $42,63647 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $712 | $41,68830 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $40 | $1,00850 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 259 nephrology providers in Arizona.
Other nephrology in Chandler
- Joseph ZhaoChandler$7K
- Bassam ShakilChandler$5K
- Randy CooperPeoria$597K
- Minesh RajpalPeoria$403K
- Umar WaheedPeoria$150K
- Amer KhanPeoria$71K
- Samer Bani HaniPhoenix$54K
- Aneesha ShettyTucson$34K
- Leslie ThomasPhoenix$22K
- Alexander NimriPhoenix$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.